Adiposs

Executive Summary

Adiposs is a Swiss biotech company founded in 2016, dedicated to developing diagnostic tools and therapies targeting adipose tissue biology. Its lead asset, ImageBAT™, is a first-in-class contrast agent designed to image brown adipose tissue (BAT) non-invasively. By enabling precise visualization of BAT, ImageBAT has the potential to revolutionize the assessment of metabolic health, allowing clinicians to identify patients at higher risk for conditions such as cancer, obesity, and metabolic disorders. The company's innovative approach addresses a critical gap in metabolic diagnostics, as BAT activity is linked to energy expenditure and metabolic regulation. Adiposs operates in the early-stage biotech space, with its core focus on advancing ImageBAT through development and regulatory pathways. While specific funding and clinical stage details are not publicly disclosed, the company's technology could attract strategic partnerships with pharmaceutical or diagnostic firms interested in metabolic imaging. The successful validation of ImageBAT in clinical settings could pave the way for broader applications in personalized medicine and therapeutic monitoring. With a strong scientific foundation and a clear unmet need, Adiposs represents a promising but early-stage opportunity in the metabolic diagnostics landscape.

Upcoming Catalysts (preview)

• TBDFDA or EMA regulatory meeting/designation for ImageBAT40% success
• TBDClinical trial results or initiation of pivotal study35% success
• TBDStrategic partnership or licensing agreement50% success